- Conditions
- Asthma
- Interventions
- Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 11
- States / cities
- Madera, California • San Diego, California • Savannah, Georgia + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 13,797
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Other Surgical Procedures
- Interventions
- Surgical Video Assessments, Video Recording of CAB
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 6
- States / cities
- Dallas, Texas • Houston, Texas • San Antonio, Texas
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 548 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 30
- States / cities
- La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
- Conditions
- Apparent Mineralocorticoid Excess Syndrome
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York • Dallas, Texas
- Conditions
- Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
- Interventions
- PCA plus methadone (Experimental), PCA Alone (SOC)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Interventions
- AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,015 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 142 more
- Conditions
- Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
- Interventions
- EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
- Drug
- Lead sponsor
- enGene, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
- Interventions
- MK-3475, INCB024360
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 24
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Bipolar I Disorder, Unspecified, With Psychotic Features, Bipolar I Disorder, Unspecified, Without Psychotic Features
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
- Interventions
- rigosertib sodium
- Drug
- Lead sponsor
- Traws Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 14
- States / cities
- Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more
- Conditions
- Predisposition, Genetic
- Interventions
- Not listed
- Lead sponsor
- Medneon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2030
- U.S. locations
- 5
- States / cities
- Redding, California • Barrington, Illinois • Troy, Michigan + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2189265, Metoprolol, Lisinopril, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 3
- States / cities
- Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas
- Conditions
- Major Depressive Disorder
- Interventions
- Agomelatine, paroxetine, placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • National City, California • Orange, California + 40 more
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- teriparatide, raloxifene, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years to 85 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 13
- States / cities
- Anaheim, California • Oakland, California • Altamonte Springs, Florida + 10 more
- Conditions
- Back Pain
- Interventions
- Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1998
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Placebo, AST-120
- Drug
- Lead sponsor
- Tanabe Pharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,015 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 46
- States / cities
- Tuscaloosa, Alabama • Hot Springs, Arkansas • Bakersfield, California + 43 more
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Obinutuzumab, Corticosteroids
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 24 more
- Conditions
- Glioblastoma
- Interventions
- VB-111 + bevacizumab, Bevacizumab
- Drug
- Lead sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Rogers, Arizona • Irvine, California + 40 more
- Conditions
- Partial Epilepsies, Partial Onset Seizures
- Interventions
- lacosamide
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
- Conditions
- Heart Failure, Congestive and Microalbuminuria
- Interventions
- metoprolol xl, carvedilol MR, lisinopril
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more
- Conditions
- Nemaline Myopathy
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
- Conditions
- SARS-CoV2 Infection
- Interventions
- Remdesivir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Placebo, Tozorakimab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 1,454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more
- Conditions
- Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
- Interventions
- Immunoglobulins Intravenous (Human)
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 4 Years to 71 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 7 more